Nuevas Soluciones en DP, Sirven? Prueba en diabéticos con transporte peritoneal alto y promedio alto Dr. José Ramón Paniagua Sierra Unidad de Investigación.

Slides:



Advertisements
Similar presentations
+ Understanding Kidney Disease and Renal Dialysis Brooke Grussing Concordia College.
Advertisements

M ETABOLIC S YNDROME IN P ERIONIAL D IALYSIS Dr. Sreelatha Calicut.
Dr. Leonid Feldman Nephrology and Hypertension Division Assaf Harofeh Medical Center November, 2007 Peritoneal Dialysis.
The Importance of Residual Renal Function Dr Paul Tam June 11, 2010.
End Stage Renal Disease in Children. End stage kidney disease occurs when the kidneys are no longer able to function at a level that is necessary for.
Dr. Kenneth Thomas, MD Diabetes Support Group Starkville, MS 7/10/12.
Chronic Kidney Disease and Heart Disease: Understanding the Link Contributed by Elaine M. Koontz, RD, LD/N Review Date 8/13 R-0629 Provided Courtesy of.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Peritoneal Dialysis Adequacy & Prescription Management
ESAs and Outcomes in CKD Patients Philip Lui PharmD The 13th Annual Contemporary Therapeutic Issues in Cardiovascular Disease May 8, 2010.
Reference Avram MM, et al. Hemoglobin predicts long-term survival in dialysis patients: a 15-year single-center longitudinal study and a correlation trend.
Temporal Trends in the Prevalence of Diabetic Kidney Disease in the United States Ian H. de Boer, MD, MS, Tessa C. Rue, MS, Yoshio N. Hall, MD, Patrick.
Dialysis Facility Compare Valarie Ashby Co-Managing Director UM-KECC.
Anatomy and Physiology of Peritoneal Dialysis
Effectiveness of interactive web-based lifestyle program on prevention of cardiovascular diseases risk factors in patient with metabolic syndrome: a randomized.
PRINCIPLES OF DIALYSIS DR SAAD ALSHOHAIB ASSOCIATE PROFESSOR IN MEDICINE AND NEPHROLOGY KAUH.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Hemoglobin A 1c in Hemodialysis Patients Source: Ix JH. Hemoglobin A1c in hemodialysis patients: Should one size fit all? Clin J Am Soc Nephrol. 2010;5:1539–1541.
Supplementation of vitamin C reduces blood glucose and improves glycosylated hemoglobin in T2DM Mellitus: a randomized, double-blind study. Dakhale GN,
Urinary System. Secreted Substances Secreted Substances Hydroxybenzoates Hydroxybenzoates Hippurates Hippurates Neurotransmitters (dopamine) Neurotransmitters.
Diseases of the Renal System KNH 413. CKD - Renal Replacement Therapy Hemodialysis (HD) or Peritoneal Dialysis (PD) Type based on underlying kidney disease.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
Joint Effects of Routine Blood Pressure Lowering and Intensive Glucose Control ADVANCE Adapted from EASD 2008.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
PERITONEAL MEMBRANE CHARACTERISTICS IN SAUDI PATIENTS Prof. Jamal Alwakeel, Dr Saira Usama Dr Abdulkareem Alsuwaida, Dr Mohammad AL Ghonaim, Dr Akram.
Leveraging Weight Loss in the Treatment of Type 2 Diabetes Part 1 of 4.
Dr. Amr S. Moustafa, MD, PhD Clinical Chemistry Unit, Pathology Dept. College of Medicine, King Saud University.
Evaluation of Renal Function. Normal volumes and composition of electrolytes in various body fluid compartments are essential for maintenance of life.
Background  Obesity is an extremely common problem ~ 1/3 of adult Americans are obese  Patients commonly ask physicians for advice on weight loss, yet.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Red Cell Distribution Width (RDW) as a Novel Prognostic Marker in Heart Failure: Data from the CHARM Program and the Duke Databank.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients Dr. Mya Thandar.
DIALYSIS Dr. Frank Edwin.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
Dietary Issues in Renal Complications Ulrich Wahl, Tamworth, 2010.
“Adequacy in PD prescription What, How, When?
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
Principles of Peritoneal Dialysis
Diabetes And Hemodialysis 1 Dr.Ruba Nashawati. 2.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Cardiovascular Disease and Antihypertensives The RENAAL Trial Reference Brunner BM, and the RENAAL study group. Effects of losartan on renal and cardiovascular.
- Higher SBP visit-to-visit variability (SBV) has been associated
Nephrology Journal Club The SPRINT Trial Parker Gregg
Effects of Uric acid- lowering therapy on renal outcomes: a systematic review and meta-analysis Nephrol Dial Transplant (2014) 29: Vaughan Washco.
Optimization of pre-ESRD care: The key to improved dialysis outcomes
The HEMO Study Hemodialysis (HEMO) Study Reference
The ADEMEX Trial Adequacy of PD in Mexico Reference
Intensive Hemodialysis: Applied Clinical Practice
1938: First treatment of AKI with PD
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
CARDIOVASCULAR CORELATIONS IN CHILDREN WITH END STAGE RENAL DISEASE
The CANUSA Trial Reference
Endocrine System KNH 411.
Endocrine System KNH 411.
Renal Disease Filtration, glomeruli generate removal ultrafiltrate of the plasma based on size and charge of molecules End products include urea, creatinine,
Systolic Blood Pressure Intervention Trial (SPRINT)
Endocrine System KNH 411.
These slides highlight an educational report from a late-breaking clinical trials presentation at the 58th Annual Scientific Session of the American College.
Benefits of preserving residual renal function in peritoneal dialysis
Endocrine System KNH 411.
Endocrine System KNH 411.
Endocrine System KNH 411.
Volume 70, Issue 3, Pages (August 2006)
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Presentation transcript:

Nuevas Soluciones en DP, Sirven? Prueba en diabéticos con transporte peritoneal alto y promedio alto Dr. José Ramón Paniagua Sierra Unidad de Investigación Médica en Enfermedades Nefrológicas. UMAE HE CMN S XXI, México, D. F. Dr. José Ramón Paniagua Sierra Unidad de Investigación Médica en Enfermedades Nefrológicas. UMAE HE CMN S XXI, México, D. F.

Background  Sodium intake and extracellular fluid volume expansion have been associated with hypertension and cardiovascular mortality in the general population  Extracellular fluid volume expansion is the most frequent cause of hypertension in ESRD patients with or without dialysis treatment. It has been related with other predictors of death like left ventricular hypertrophy  Extracellular fluid volume expansion has also been related with lost of RRF and low grade chronic inflammation  Sodium intake and extracellular fluid volume expansion have been associated with hypertension and cardiovascular mortality in the general population  Extracellular fluid volume expansion is the most frequent cause of hypertension in ESRD patients with or without dialysis treatment. It has been related with other predictors of death like left ventricular hypertrophy  Extracellular fluid volume expansion has also been related with lost of RRF and low grade chronic inflammation

Background  Several clinical conditions and serum markers are now known as predictors of clinical outcomes in ESRD patients. Among them: Diabetes Cardiovascular morbidity (LVH, HT, proBNP, TNt) Malnutrition (SA, TF, LBM, TBW, MAC) Inflammation (CRP, TNF , IL-6) Fluid and sodium removal  The variety of predictors suggest a complex network of interactions between them. ECFv expansion may have a significant role  Several clinical conditions and serum markers are now known as predictors of clinical outcomes in ESRD patients. Among them: Diabetes Cardiovascular morbidity (LVH, HT, proBNP, TNt) Malnutrition (SA, TF, LBM, TBW, MAC) Inflammation (CRP, TNF , IL-6) Fluid and sodium removal  The variety of predictors suggest a complex network of interactions between them. ECFv expansion may have a significant role

ADEMEX Mortality

IL 6 and mortality

C-reactive protein and mortality

Fluid removal and mortality

pBNP and mortality

Relationship of inflammation, ECFv and DM MALNUTRITION OR WASTING MALNUTRITION OR WASTING INFLAMMATION CV DISEASE CV DEATH

Relationship of inflammation,ECFv and DM MALNUTRITION OR WASTING MALNUTRITION OR WASTING INFLAMMATION CV DISEASE CV DEATH ECFv EXPANSION ECFv EXPANSION PERITONEAL PERMEABILITY PERITONEAL PERMEABILITY  PRESSURE  VOLUME  PRESSURE  VOLUME

Relationship of inflammation, ECFv and DM MALNUTRITION OR WASTING MALNUTRITION OR WASTING INFLAMMATION CV DISEASE CV DEATH ECFv EXPANSION ECFv EXPANSION PERITONEAL PERMEABILITY PERITONEAL PERMEABILITY  PRESSURE  VOLUME  PRESSURE  VOLUME D M CHO-PTG D M CHO-PTG      ?        

Background  The success in the control of ECFv of PD patients depends on: Sodium and fluid intake Residual renal function Peritoneal transport type (PET) Type and concentration of the osmotic agent in the dialysis solution  The success in the control of ECFv of PD patients depends on: Sodium and fluid intake Residual renal function Peritoneal transport type (PET) Type and concentration of the osmotic agent in the dialysis solution

Background  Glucose is the most commonly used osmotic agent. Disadvantages: Damage of mesothelial cells by glucose degradation products and advanced glycation products Peritoneal glucose absorption. Then:  Loss of osmotic gradient = deficient UF  Obesity, low protein intake, impairment in metabolic control  Diabetes increases glucose disadvantages  Glucose is the most commonly used osmotic agent. Disadvantages: Damage of mesothelial cells by glucose degradation products and advanced glycation products Peritoneal glucose absorption. Then:  Loss of osmotic gradient = deficient UF  Obesity, low protein intake, impairment in metabolic control  Diabetes increases glucose disadvantages

Icodextrin  It has been successfully used as osmotic agent, particularly in high transporters  It does not have the glucose disadvantages  It has been successfully used as osmotic agent, particularly in high transporters  It does not have the glucose disadvantages Chain α (1→4) Chain α (1→6)

Background  In spite of the potential benefits of icodextrin in increasing ultrafiltration without metabolic disadvantages in high-transport diabetic PD patients, RCT are not available  Information is important for populations with high rates of diabetics in their PD programs. This is the case of Mexico and other countries.  In spite of the potential benefits of icodextrin in increasing ultrafiltration without metabolic disadvantages in high-transport diabetic PD patients, RCT are not available  Information is important for populations with high rates of diabetics in their PD programs. This is the case of Mexico and other countries.

Objective  Primary outcomes: Improvement in peritoneal UF Reduction of ECFv Control of BP, edema and CV function Metabolic control  Primary outcomes: Improvement in peritoneal UF Reduction of ECFv Control of BP, edema and CV function Metabolic control  Secondary outcomes: Nutrition improvement Control of inflammation Quality of life Mortality  Secondary outcomes: Nutrition improvement Control of inflammation Quality of life Mortality To test the clinical usefulness of icodextrin based solution in high transport diabetic patients in PD

Study design Target of treatment  To reach control of blood pressure and edema through the increment in peritoneal ultrafiltration Treatments. 3x2L, 1.5% glucose exchanges plus:  Control group: Glucose-based solutions, at least 1 bag with 2.5% glucose in the longest dwell  Icodextrin group: Icodextrin-based solution (7.5%) in the longest dwell Replacement of 1.5% for 2.5 or 4.25% glucose was allowed to reach the treatment goal  To reach control of blood pressure and edema through the increment in peritoneal ultrafiltration Treatments. 3x2L, 1.5% glucose exchanges plus:  Control group: Glucose-based solutions, at least 1 bag with 2.5% glucose in the longest dwell  Icodextrin group: Icodextrin-based solution (7.5%) in the longest dwell Replacement of 1.5% for 2.5 or 4.25% glucose was allowed to reach the treatment goal

Study design  Randomized clinical trial Open label Multicentric (HGZ 8; HGZ 25; HGZ 27; HGZ 47. IMSS, México, D. F.) Central randomization Central laboratory (UIMEN) Follow-up: 6 months; 12 months  Randomized clinical trial Open label Multicentric (HGZ 8; HGZ 25; HGZ 27; HGZ 47. IMSS, México, D. F.) Central randomization Central laboratory (UIMEN) Follow-up: 6 months; 12 months

 Inclusion criteria Diabetics Adults High and high average transport Without selection by gender or time on dialysis  No inclusion criteria Seropositivity HB, HIV CA, immunosuppression  Inclusion criteria Diabetics Adults High and high average transport Without selection by gender or time on dialysis  No inclusion criteria Seropositivity HB, HIV CA, immunosuppression  Exclusion criteria Patient decision Medical decision Transplant Change of address  Exclusion criteria Patient decision Medical decision Transplant Change of address Material and methods Patients

Results Without differences between groups at baseline in:  Age  Gender  Blood pressure  Body composition  Dialysis adequacy  Biochemical parameters  Comorbidity Without differences between groups at baseline in:  Age  Gender  Blood pressure  Body composition  Dialysis adequacy  Biochemical parameters  Comorbidity

Results  Prescription In the control group two thirds of the patients needed more than one bag of 2.5% glucose or at least one bag of 4.25% glucose. In the icodextrin group only 9% needed a bag with more than 1.5% of glucose  Prescription In the control group two thirds of the patients needed more than one bag of 2.5% glucose or at least one bag of 4.25% glucose. In the icodextrin group only 9% needed a bag with more than 1.5% of glucose

Results Actual prescription

Results Metabolic control

Results

Mean±EEM *p<0.05; ** p<0.03; *** p<0.01 vs Control ‡p<0.05; ‡ ‡ p<0.03; ‡ ‡ ‡ p<0.01 vs Basal Mean±EEM *p<0.05; ** p<0.03; *** p<0.01 vs Control ‡p<0.05; ‡ ‡ p<0.03; ‡ ‡ ‡ p<0.01 vs Basal Results

Body fluids and cardiovascular parameters

Results Ultrafiltration

Results

Results BP (in office)

Results BP (ambulatory) **  ** * *** ** ** *= p<0.05 vs basal; **= p<0.01 vs basal;  = p<0.05 vs glucose group;   = p<0.01 vs glucose group

Results EKG basal

Results EKG changes

Results Icodextrin metabolites

Results Mortality ( ) = number of patients. *= Death related to dropout cause. [ ] Dialysis modality at the time of death Death was considered related to dropout case if occurred in the 30 days after dropout and the final diagnosis was related to the technique failure

Results Mortality

Annual Cost of Patient on Dialysis $- $50 $100 $150 $200 $250 $300 APDCAPD Icodextrin CAPDDPHD INSTHD SUB x1000 ConsumablesPharmacologic tLaboratoryHospitalizationPeritonitisCatheter dysfunction DisabilityEmergencyPersonalInfrastructureTransport Results

Relationship of inflammation, ECFv and DM MALNUTRITION OR WASTING MALNUTRITION OR WASTING INFLAMMATION CV DISEASE CV DEATH ECFv EXPANSION ECFv EXPANSION PERITONEAL PERMEABILITY PERITONEAL PERMEABILITY  PRESSURE  VOLUME  PRESSURE  VOLUME D M CHO-PTG D M CHO-PTG X   ? xx xx xx xx X  ICODEXTRIN

Conclusion  Patients in the Icodextrin group had better metabolic control and nutrition  Icodextrin-based solution was superior to glucose- based solution in fluid and sodium removal.  Patients in the Icodextrin group had better control of blood pressure and reduction in left ventricular mass  Patients in the Icodextrin group had better metabolic control and nutrition  Icodextrin-based solution was superior to glucose- based solution in fluid and sodium removal.  Patients in the Icodextrin group had better control of blood pressure and reduction in left ventricular mass